Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-07-19
2005-07-19
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S350000
Reexamination Certificate
active
06919341
ABSTRACT:
In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
REFERENCES:
patent: 0 778 277 (1997-06-01), None
patent: WO 88/04298 (1988-06-01), None
patent: WO 02/06286 (2002-01-01), None
patent: WO 02/10162 (2002-02-01), None
patent: WO 02 50079 (2002-06-01), None
patent: WO 02 060492 (2002-08-01), None
patent: WO 02/060492 (2002-08-01), None
patent: WO 03/089434 (2003-10-01), None
Douglas, Jr. Introduction to Viral Diseases, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1739-1747, 1996.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
LuValle et al., Cell Cycle Control in Growth Plate Chondocytes, Frontiers in Bioscience 5, d493-503, May 2000. (http://bioscience.igh.cnrs.fr/2000/v5/d/luvalle/fulltext.asp).
Blain et al. Different Integration of the Cyclin-dependent Kinase (Cdk) Inhibitor p27Kipi with Cyclin A-Cdk2 and Cyclin D2-Cdk4, The Journal of Biological Chemistry, vol. 272, No. 41, pp. 25863-25872, 1997.
Viste, O. et al., “Imidazo(1,2-a)pyrazine Derivatives with Brochodilatory and Cyclic Nucleotide Phosphodiesterase Inhibitory Activities”,Bioorganic&Med. Chem., 7: 1059-1065 (1999).
K. Zurbonsen et al., “Antiproliferative effects of Imidazo[1,2-α]pyrazine Derivatives on the Dami Cell Line”,Biochemical Pharmacology, 54: 365-371 (1997).
K. Zurbonsen et al., “Apoptotic effects of Imidazo[1,2-α]pyrazine Derivatives in the Human Dami Line”,European Journal of Pharmacology, 320: 215-221. (1997).
A. Sanderowicz et al., “Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms”,J. Clin. Oncology, 16: 2986-2999 (1998).
J. Vesely et al., “Inhibition of Cyclin-Dependent Kinases by Purine Analogues”,Eur. J. Biochem., 224: 771-786 (1994).
I. Meijer et al., “Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases cdc2, cdk2 and cdk5”,Eur. J. Biochem., 243: 527-536 (1997).
K. S. Kim et al., “Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activites”,J. Medicinal Chemistry, 45: 3905-3927 (2002).
Vesely et al., “Inhibition of Cyclin-Dependent Kinases by Purine Analogues”,Eur. J. Biochem(1994), 224: 771-786.
Senderowicz et al., “Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients With Refractory Neoplasms”,Journal of Clinical Oncology(Sep. 1998), 16(9): 2986-2999.
Meijer et al., “Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5”,Eur. J. Biochem. (1997), 243: 527-536.
Bible et al., “Cytotoxic Synergy between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration”,Cancer Research(Aug. 15, 1997), 57: 3375-3380.
Shiota et al., “Synthesis and Structure- Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5α]pyrimidine Derivatives”,Chem. Pharm. Bull. (1999), 47(7): 928-938.
Yasuo Makisumi, “Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5-α]pyrimidines.”,Chem. Pharm. Bull. (1962), 10: 620-626.
Doll Ronald J.
Dwyer Michael P.
Girijavallabhan Viyyoor M.
Guzi Timothy J.
Mallams Alan
Kalyanaraman Palaiyur S.
Rao Deepak
Schering Corporation
LandOfFree
Imidazopyrazines as cyclin dependent kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazopyrazines as cyclin dependent kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazopyrazines as cyclin dependent kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3405369